# Why a kidney trial measured body water as well as lean mass

- Article ID: research-329
- Product: SEMA / IGF-1 LR3 (sema-igf-1-lr3-708, sema-igf-1-lr3-709)
- Canonical page: https://heritagebiolabs.com/research-library/articles/329-why-a-kidney-trial-measured-body-water-as-well-as-lean-mass
- Product collection: https://heritagebiolabs.com/research-library/products/sema-igf-1-lr3
- Product page: https://heritagebiolabs.com/product/sema-igf-1-lr3-708
- Product page: https://heritagebiolabs.com/product/sema-igf-1-lr3-709
- Reading focus: Methods & identity (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2023, 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

A peptide is a short chain of amino acids linked by peptide bonds. Its sequence can help it engage a receptor that controls a biological process. Semaglutide acts at the GLP-1 receptor. IGF-1 LR3 is an altered, extended version of the growth-factor protein IGF-1. The 2026 SMART analysis studied semaglutide alone versus placebo and asked whether changes in body composition were related to kidney measurements. [1, 2]

The analysis used data from 101 adults with chronic kidney disease and overweight or obesity without type 2 diabetes. The investigators used bioimpedance, which estimates body composition using the passage of a small electrical signal. They recorded lean body mass, fat mass and water outside cells. They also measured how well the kidneys filtered a test substance and compared that measurement with estimates based on substances found in the blood. [1]

Semaglutide reduced measured lean and fat mass over 24 weeks compared with placebo. The researchers did not find a correlation between those changes and changes in measured or estimated filtration. They also reported a decrease in extracellular water. These outcomes help distinguish tissue composition, body fluid and filtration, each of which can be represented by a different measurement in the same participant. [1]

If researchers were studying whether adding IGF-1 LR3 affected body composition, they would need to separate changes in fluid from changes in tissue and assess which intervention was responsible. The SMART study can help explain the choice of measurements. It did not administer the named pair. Findings about body mass and filtration with semaglutide alone cannot predict what would happen when another growth-factor signal is introduced. [1, 2]

## Sources

1. H. J. L. Heerspink et al. Effects of Semaglutide on Body Composition and GFR: A Prespecified Analysis of the SMART Trial. Clinical Journal of the American Society of Nephrology (publication 2026-04-30). <https://pubmed.ncbi.nlm.nih.gov/42308057/>
2. Z. Lu et al. Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris. Applied Microbiology and Biotechnology (publication 2023-06). <https://pubmed.ncbi.nlm.nih.gov/37261455/>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 066 - Selank and SEMA IGF-1 LR3.docx; article 329; content SHA-256 471b3a83a9ad1145d3254a880cee7913d1591641f81bad48ec17d522d7fc2acd.
